Victory Capital Management Inc. Reduces Position in GW Pharmaceuticals PLC- (GWPH)

Victory Capital Management Inc. lowered its position in GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 13.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 266,220 shares of the biopharmaceutical company’s stock after selling 40,290 shares during the period. Victory Capital Management Inc. owned 0.88% of GW Pharmaceuticals PLC- worth $45,987,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in GWPH. Flagship Harbor Advisors LLC acquired a new position in GW Pharmaceuticals PLC- during the second quarter valued at approximately $109,000. Envestnet Asset Management Inc. acquired a new position in GW Pharmaceuticals PLC- during the second quarter valued at approximately $119,000. Cowen Prime Services LLC grew its holdings in GW Pharmaceuticals PLC- by 708.0% during the second quarter. Cowen Prime Services LLC now owns 1,010 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 885 shares during the last quarter. NumerixS Investment Technologies Inc acquired a new position in GW Pharmaceuticals PLC- during the second quarter valued at approximately $166,000. Finally, BNP Paribas Arbitrage SA grew its holdings in GW Pharmaceuticals PLC- by 497.0% during the second quarter. BNP Paribas Arbitrage SA now owns 1,200 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 999 shares during the last quarter. Hedge funds and other institutional investors own 70.02% of the company’s stock.

GWPH opened at $137.87 on Friday. GW Pharmaceuticals PLC- has a 1-year low of $105.12 and a 1-year high of $179.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.21 and a current ratio of 8.67.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating the consensus estimate of ($2.40) by $1.14. GW Pharmaceuticals PLC- had a negative return on equity of 47.65% and a negative net margin of 1,392.61%. The company had revenue of $3.46 million during the quarter, compared to analysts’ expectations of $2.00 million. As a group, equities research analysts anticipate that GW Pharmaceuticals PLC- will post -9.13 EPS for the current fiscal year.

Several equities analysts have commented on GWPH shares. Morgan Stanley set a $227.00 price target on GW Pharmaceuticals PLC- and gave the company a “buy” rating in a report on Thursday, October 11th. Zacks Investment Research downgraded GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a report on Friday, August 10th. BidaskClub downgraded GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a report on Wednesday, August 1st. Stifel Nicolaus began coverage on GW Pharmaceuticals PLC- in a research report on Tuesday, August 14th. They issued a “buy” rating and a $181.00 price objective for the company. Finally, ValuEngine cut GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Thursday, August 2nd. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $184.13.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/11/10/victory-capital-management-inc-reduces-position-in-gw-pharmaceuticals-plc-gwph.html.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Story: Google Finance Portfolio

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply